The FDA has granted Grants Accelerated Approval to Rybrevant Faspro for some adults with recurrent or metastatic head and neck squamous cell carcinoma, expanding treatment options after earlier therapies. The drug is approved for patients whose disease progressed on or after platinum-based chemotherapy and immunotherapy.
The decision marks the first drug approval in 10 years for patients with recurrent or metastatic HNSCC who had received prior platinum-based chemotherapy, according to the FDA. The agency said the treatment is not indicated for oropharyngeal squamous cell carcinoma associated with human papillomavirus, or HPV.
Grants Accelerated Approval Based on Tumor Response
The FDA based its decision on an open-label, multicenter trial involving 102 patients with recurrent or metastatic HNSCC. In that study, Rybrevant Faspro produced an overall response rate of 42%. That measure means patients’ tumors decreased in size or disappeared.
Among patients who responded, 56% had a response lasting six months or longer. The FDA compared the result with currently approved therapies, which it said are associated with an overall response rate of around 20% or less and poor outcomes. The agency described the trial results as showing more than double the percentage of patients responding compared with those therapies.
Those figures describe tumor response, not confirmed long-term benefit. The FDA said it has not yet been confirmed whether the response results will translate into a clinically meaningful improvement in long-term outcomes. It therefore required confirmatory studies to verify and describe the drug’s clinical benefit.
Accelerated approval allows earlier authorization for drugs treating serious conditions and addressing unmet medical needs, based on surrogate or intermediate endpoints. For this decision, the FDA cited overall response rate and duration of response. The required follow-up studies are intended to establish whether those measures correspond with a meaningful clinical benefit.
Confirmatory Studies Will Test Clinical Benefit
The approval leaves an important evidence question open: whether the observed responses lead to lasting benefit for patients. The FDA’s requirement for confirmatory studies makes that question part of the next stage of evidence gathering, rather than a conclusion established by the current results.
Other Meditech Today coverage has examined experimental brain cancer treatment and how researchers approach treatment development. A separate report on an ongoing Phase 2b trial illustrates that development announcements and clinical outcomes are distinct. These stories concern different diseases and therapies; they offer context for the stages of evidence behind medical treatments, not additional findings about Rybrevant Faspro.
FDA Lists Warnings and Precautions
The prescribing information for Rybrevant Faspro as a single agent includes warnings and precautions for hypersensitivity and administration-related reactions, interstitial lung disease or pneumonitis, dermatologic adverse reactions, ocular toxicity, and harm to an unborn baby. The FDA’s announcement identifies those safety topics but does not provide rates or additional detail for each in the release.
The agency granted Rybrevant Faspro Breakthrough Therapy designation for this indication. Approval went to Janssen Biotech, Inc. The FDA said the treatment offers a new option for patients and physicians, while emphasizing that confirmatory studies must verify and describe clinical benefit. The next stated step is completion of those studies, which will address the unresolved question of longer-term outcomes.
